Pharming Group (NASDAQ:PHAR) Shares Gap Down – Should You Sell?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) shares gapped down prior to trading on Friday . The stock had previously closed at $17.75, but opened at $16.72. Pharming Group shares last traded at $17.22, with a volume of 17,729 shares changing hands.

Analysts Set New Price Targets

A number of research firms have commented on PHAR. Zacks Research raised shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pharming Group in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Pharming Group currently has a consensus rating of “Buy” and a consensus price target of $30.00.

Pharming Group Stock Down 4.3%

The business’s fifty day moving average is $14.96 and its two-hundred day moving average is $12.77. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -1,713.09 and a beta of 0.03. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. The company had revenue of $97.30 million for the quarter, compared to analyst estimates of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. Pharming Group has set its FY 2025 guidance at EPS. Equities analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,979 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.